JPRN-UMIN000012832招募中未知
Panitumumab plus mFOLFOX6 therapy for colorectal cancer patients of RAS wild with potential resectable metastases in relation to early tumor shrinkage - Panitumumab plus mFOLFOX6 therapy for RAS wild
Chubu Clinical Oncology Group(CCOG)0 个研究点目标入组 30 人开始时间: 2014年1月15日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(1)Pleural effision or ascites or pericardial effusion to be discharged (2)Multiple malignacies to be treated (3)bleeding tendency(PT-INR ;1.5) (4)Ileus,uncontrollable peptic ulcer disease (5)Serious complications (DM, infection, diarrhea) (6)Serious heart disease (7)Previous history of severe drug-induced allergy (8)Severe neuropathy (9)With interstitial lung disease or pulmonary fibrosis (10)Pregnant (11)Disqualified by attending doctor
研究者
相似试验
已完成
2 期
Phase ll study of Panitumumab for advanced colorectal cancer which has prior therapy of Bevacizumabmetastatic colorectal cancerJPRN-UMIN000005179Yokohama city university20
招募中
2 期
mFOLFOX6+Cetuximab in Treating Patients With not Optimally Resectable Liver Metastases From Colorectal Cancerliver metastases from colorectal cancerJPRN-UMIN000004811Cancer Institute Hospital of Japanese Foundation for Cancer Research45
已完成
3 期
Panitumumab and RAS, Diagnostically-useful Gene Mutation for mCRCColorectal CancerNCT02394795Takeda823
招募中
2 期
Phase2 study of mFOLFOX6 plus nivolumab for patients with ESCCEsophageal CancerJPRN-jRCTs031230630Kubota Yohei33
已完成
2 期
Phase II study of panitumumab with FOLFOX or FOLFIRI as 1st line treatment in patients with metastatic colorectal cancer in JapaColorectal cancerJPRN-UMIN000004991Tokyo Medical and Dental University165